Kohjin Bio Co.,Ltd. AI Stock Analysis
Want to see JP:177A full AI Analyst Report?
Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis
Kohjin Bio Co.,Ltd.
(TSE/TYO:177A)
The score is primarily held back by weakening financial quality (negative revenue growth, sharp margin compression, and negative free cash flow) and a clearly bearish technical setup (price below key moving averages with negative MACD). A stronger balance sheet and manageable leverage provide some stability, but valuation remains only middling due to a relatively high P/E and a modest dividend yield.
Kohjin Bio Co.,Ltd. (177A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.39B
- Dividend Yield
- 1.51%
- Average Volume (3M)
- 3,148
- Price to Earnings (P/E)
- 26.8
- Beta (1Y)
- 0.38
- Revenue Growth
- -15.78%
- EPS Growth
- -104.11%
- Country
- Japan
- Employees
- 176
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Kohjin Bio Co.,Ltd. Business Overview & Revenue Model
Company Description
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materi...
How the Company Makes Money
null
Kohjin Bio Co.,Ltd. Financial Statement Overview
Summary
Balance sheet strength is a positive (improving leverage with debt-to-equity ~0.37 in 2026), but overall performance is pressured by a step-down in fundamentals: revenue turned negative (-4.7% in 2026) and profitability compressed sharply (net margin ~5.1% vs. ~15.3% in 2025). Cash conversion is the biggest drag, with free cash flow swinging negative in 2026 (-Â¥281M) and showing volatility versus earnings.
Income Statement
58NeutralBalance Sheet
71PositiveCash Flow
41Neutral| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.18B | 5.21B | 4.94B | 4.77B | 4.74B | 3.95B |
| Gross Profit | 2.31B | 2.37B | 1.86B | 1.88B | 2.45B | 2.04B |
| EBITDA | 1.26B | 1.41B | 766.46M | 958.10M | 1.44B | 1.14B |
| Net Income | 714.00M | 794.76M | 251.02M | 384.00M | 829.79M | 587.67M |
Balance Sheet | ||||||
| Total Assets | 9.17B | 9.12B | 8.90B | 6.64B | 6.20B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 3.10B | 3.15B | 2.49B | 1.73B | 1.46B | 1.73B |
| Total Debt | 1.99B | 2.39B | 2.19B | 2.47B | 2.10B | 2.23B |
| Total Liabilities | 3.46B | 3.34B | 2.96B | 3.30B | 3.18B | 3.38B |
| Stockholders Equity | 5.71B | 5.78B | 5.95B | 3.34B | 3.02B | 2.22B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 28.05M | -280.78M | 260.88M | -99.57M | 559.44M |
| Operating Cash Flow | 0 | 915.55M | 698.51M | 823.68M | 461.15M | 762.98M |
| Investing Cash Flow | 0 | -1.09B | -867.67M | -577.35M | -575.46M | 82.78M |
| Financing Cash Flow | 0 | 1.38B | -320.76M | -1.35M | -172.21M | -360.17M |
Kohjin Bio Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 664.00 is below the 20-day moving average (MA) of 744.35, below the 50-day MA of 795.90, and below the 200-day MA of 1040.18, indicating a bearish trend. The MACD of -38.15 indicates Positive momentum. The RSI at 23.84 is Positive, neither overbought nor oversold. The STOCH value of 2.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.
Kohjin Bio Co.,Ltd. Peers Comparison
Overall Rating
- JP:177A50Neutral
JP:497845Neutral
JP:777442Neutral
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:177A | 50Neutral | JPY 3.39B | 26.76 | ― | 1.51% | -15.78% | -104.11% |
| JP:4978 | 45Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 26.52B | -73.78 | ― | ― | 17.05% | 10.47% |
| JP:7776 | 39Underperform | JPY 6.70B | -5.83 | ― | ― | -49.43% | -3.77% |
| JP:4599 | 38Underperform | JPY 7.33B | -3.94 | ― | ― | ― | 4.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:177A | Kohjin Bio Co.,Ltd. | 664.00 | -895.84 | -57.43% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026